Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs

Richard L. Mackman, Lijun Zhang, Vidya Prasad, Constantine G. Boojamra, Janet Douglas, Deborah Grant, Hon Hui, Choung U. Kim, Genevieve Laflamme, Jay Parrish, Antitsa D. Stoycheva, Swami Swaminathan, KeYu Wang, Tomas Cihlar

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Phosphonomethoxy nucleoside analogs of the thymine containing nucleoside reverse transcriptase inhibitors (NRTIs), 3′-azido-2′,3′-dideoxythymidine (AZT), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), and 2′,3′-dideoxythymidine (ddT), were synthesized. The anti-HIV activity against wild-type and several major nucleoside-resistant strains of HIV-1 was evaluated together with the inhibition of wild-type HIV reverse transcriptase (RT). Phosphonomethoxy analog of d4T, 8 (d4TP), demonstrated antiviral activity with an EC50 value of 26 μM, whereas, phosphonomethoxy analogs of ddT, 7 (ddTP), and AZT, 6 (AZTP), were both inactive at concentrations up to 200 μM. Bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs improved the anti-HIV activity of 7 and 8 by >150-fold and 29-fold, respectively, allowing for antiviral resistance to be determined. The K65R RT mutant virus was more resistant to the bisPOC prodrugs of 7 and 8 than bisPOC PMPA (tenofovir DF) 1. However, bisPOC prodrug of 7 demonstrated superior resistance toward the RT virus containing multiple thymidine analog mutations (6TAMs) indicating that new phosphonate nucleoside analogs may be suitable for targeting clinically relevant nucleoside resistant HIV-1 strains.

Original languageEnglish (US)
Pages (from-to)5519-5528
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume15
Issue number16
DOIs
StatePublished - Aug 15 2007
Externally publishedYes

Fingerprint

Prodrugs
Nucleosides
Thymidine
HIV
Tenofovir
RNA-Directed DNA Polymerase
Viruses
Antiviral Agents
HIV-1
HIV Reverse Transcriptase
Organophosphonates
Reverse Transcriptase Inhibitors
Thymine
Mutation

Keywords

  • Antiviral
  • Nucleosides
  • Phosphonates
  • Resistance

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. / Mackman, Richard L.; Zhang, Lijun; Prasad, Vidya; Boojamra, Constantine G.; Douglas, Janet; Grant, Deborah; Hui, Hon; Kim, Choung U.; Laflamme, Genevieve; Parrish, Jay; Stoycheva, Antitsa D.; Swaminathan, Swami; Wang, KeYu; Cihlar, Tomas.

In: Bioorganic and Medicinal Chemistry, Vol. 15, No. 16, 15.08.2007, p. 5519-5528.

Research output: Contribution to journalArticle

Mackman, RL, Zhang, L, Prasad, V, Boojamra, CG, Douglas, J, Grant, D, Hui, H, Kim, CU, Laflamme, G, Parrish, J, Stoycheva, AD, Swaminathan, S, Wang, K & Cihlar, T 2007, 'Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs', Bioorganic and Medicinal Chemistry, vol. 15, no. 16, pp. 5519-5528. https://doi.org/10.1016/j.bmc.2007.05.047
Mackman, Richard L. ; Zhang, Lijun ; Prasad, Vidya ; Boojamra, Constantine G. ; Douglas, Janet ; Grant, Deborah ; Hui, Hon ; Kim, Choung U. ; Laflamme, Genevieve ; Parrish, Jay ; Stoycheva, Antitsa D. ; Swaminathan, Swami ; Wang, KeYu ; Cihlar, Tomas. / Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. In: Bioorganic and Medicinal Chemistry. 2007 ; Vol. 15, No. 16. pp. 5519-5528.
@article{a35cd6f6bb9e4a54841d2a6bb0df6385,
title = "Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs",
abstract = "Phosphonomethoxy nucleoside analogs of the thymine containing nucleoside reverse transcriptase inhibitors (NRTIs), 3′-azido-2′,3′-dideoxythymidine (AZT), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), and 2′,3′-dideoxythymidine (ddT), were synthesized. The anti-HIV activity against wild-type and several major nucleoside-resistant strains of HIV-1 was evaluated together with the inhibition of wild-type HIV reverse transcriptase (RT). Phosphonomethoxy analog of d4T, 8 (d4TP), demonstrated antiviral activity with an EC50 value of 26 μM, whereas, phosphonomethoxy analogs of ddT, 7 (ddTP), and AZT, 6 (AZTP), were both inactive at concentrations up to 200 μM. Bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs improved the anti-HIV activity of 7 and 8 by >150-fold and 29-fold, respectively, allowing for antiviral resistance to be determined. The K65R RT mutant virus was more resistant to the bisPOC prodrugs of 7 and 8 than bisPOC PMPA (tenofovir DF) 1. However, bisPOC prodrug of 7 demonstrated superior resistance toward the RT virus containing multiple thymidine analog mutations (6TAMs) indicating that new phosphonate nucleoside analogs may be suitable for targeting clinically relevant nucleoside resistant HIV-1 strains.",
keywords = "Antiviral, Nucleosides, Phosphonates, Resistance",
author = "Mackman, {Richard L.} and Lijun Zhang and Vidya Prasad and Boojamra, {Constantine G.} and Janet Douglas and Deborah Grant and Hon Hui and Kim, {Choung U.} and Genevieve Laflamme and Jay Parrish and Stoycheva, {Antitsa D.} and Swami Swaminathan and KeYu Wang and Tomas Cihlar",
year = "2007",
month = "8",
day = "15",
doi = "10.1016/j.bmc.2007.05.047",
language = "English (US)",
volume = "15",
pages = "5519--5528",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "16",

}

TY - JOUR

T1 - Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs

AU - Mackman, Richard L.

AU - Zhang, Lijun

AU - Prasad, Vidya

AU - Boojamra, Constantine G.

AU - Douglas, Janet

AU - Grant, Deborah

AU - Hui, Hon

AU - Kim, Choung U.

AU - Laflamme, Genevieve

AU - Parrish, Jay

AU - Stoycheva, Antitsa D.

AU - Swaminathan, Swami

AU - Wang, KeYu

AU - Cihlar, Tomas

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Phosphonomethoxy nucleoside analogs of the thymine containing nucleoside reverse transcriptase inhibitors (NRTIs), 3′-azido-2′,3′-dideoxythymidine (AZT), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), and 2′,3′-dideoxythymidine (ddT), were synthesized. The anti-HIV activity against wild-type and several major nucleoside-resistant strains of HIV-1 was evaluated together with the inhibition of wild-type HIV reverse transcriptase (RT). Phosphonomethoxy analog of d4T, 8 (d4TP), demonstrated antiviral activity with an EC50 value of 26 μM, whereas, phosphonomethoxy analogs of ddT, 7 (ddTP), and AZT, 6 (AZTP), were both inactive at concentrations up to 200 μM. Bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs improved the anti-HIV activity of 7 and 8 by >150-fold and 29-fold, respectively, allowing for antiviral resistance to be determined. The K65R RT mutant virus was more resistant to the bisPOC prodrugs of 7 and 8 than bisPOC PMPA (tenofovir DF) 1. However, bisPOC prodrug of 7 demonstrated superior resistance toward the RT virus containing multiple thymidine analog mutations (6TAMs) indicating that new phosphonate nucleoside analogs may be suitable for targeting clinically relevant nucleoside resistant HIV-1 strains.

AB - Phosphonomethoxy nucleoside analogs of the thymine containing nucleoside reverse transcriptase inhibitors (NRTIs), 3′-azido-2′,3′-dideoxythymidine (AZT), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), and 2′,3′-dideoxythymidine (ddT), were synthesized. The anti-HIV activity against wild-type and several major nucleoside-resistant strains of HIV-1 was evaluated together with the inhibition of wild-type HIV reverse transcriptase (RT). Phosphonomethoxy analog of d4T, 8 (d4TP), demonstrated antiviral activity with an EC50 value of 26 μM, whereas, phosphonomethoxy analogs of ddT, 7 (ddTP), and AZT, 6 (AZTP), were both inactive at concentrations up to 200 μM. Bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs improved the anti-HIV activity of 7 and 8 by >150-fold and 29-fold, respectively, allowing for antiviral resistance to be determined. The K65R RT mutant virus was more resistant to the bisPOC prodrugs of 7 and 8 than bisPOC PMPA (tenofovir DF) 1. However, bisPOC prodrug of 7 demonstrated superior resistance toward the RT virus containing multiple thymidine analog mutations (6TAMs) indicating that new phosphonate nucleoside analogs may be suitable for targeting clinically relevant nucleoside resistant HIV-1 strains.

KW - Antiviral

KW - Nucleosides

KW - Phosphonates

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=34250789334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250789334&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2007.05.047

DO - 10.1016/j.bmc.2007.05.047

M3 - Article

VL - 15

SP - 5519

EP - 5528

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 16

ER -